BIO Comments on FDA Guidance: Clinical Pharmacology Considerations for Antibody-Drug Conjugates
May 9, 2022
On Monday, May 9th, BIO submitted comments in response to the FDA’s recent draft guidance on Clinical Pharmacology Considerations for Antibody-Drug Conjugates. In the comments submitted, BIO acknowledged the challenge FDA faces in creating a regulatory guidance that is comprehensive yet adaptable, given the diversity and complexities of ADCs today. However, BIO noted that FDA’s inclusion of a broader range of ADC products in the final guidance would be valuable to sponsors and urged FDA to provide further detail when defining and referencing various components of ADCs and their byproducts. The comments also highlighted the current challenges sponsors face in considering the inclusion of organ impairment patients and patients with interacting concomitant medications, and requested the Agency provide additional guidance on when and how these patients should be included. Lastly, BIO encouraged FDA to provide additional examples and recommendations regarding the use of physiologically based pharmacokinetic (PBPK) modeling, and to consider opportunities where sponsors could leverage existing data on ADCs with the same linker-payload (if available).
Download Full Comments Below
BIO Comments on Clinical Pharmacology Considerations for Antibody-Drug Conjugates
The Biotechnology Innovation Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit comments regarding the request and comments on the Advanced Manufacturing Technologies Designation Program Draft Guidance.
The Biotechnology Innovation Organization thanks the Food and Drug Administration for the opportunity to submit comments regarding the request for information and comments on the Food and Drug Administration's Draft Report and Plan on Best Practices…
We are writing to express our strong support for the bipartisan Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act). The legislation, which was introduced by Reps. John Joyce (R-PA) and Wiley Nickel (D-NC) in September,1 corrects a…
On Monday, May 9th, BIO submitted comments in response to the FDA’s recent draft guidance on Clinical Pharmacology Considerations for Antibody-Drug Conjugates. In the comments submitted, BIO acknowledged the challenge FDA faces in creating a regulatory guidance that is comprehensive yet adaptable, given the diversity and complexities of ADCs today. However, BIO noted that FDA’s inclusion of a broader range of ADC products in the final guidance would be valuable to sponsors and urged FDA to provide further detail when defining and referencing various components of ADCs and their byproducts. The comments also highlighted the current challenges sponsors face in considering the inclusion of organ impairment patients and patients with interacting concomitant medications, and requested the Agency provide additional guidance on when and how these patients should be included. Lastly, BIO encouraged FDA to provide additional examples and recommendations regarding the use of physiologically based pharmacokinetic (PBPK) modeling, and to consider opportunities where sponsors could leverage existing data on ADCs with the same linker-payload (if available).